Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2

Conditions

Leukemia, Myeloid, Acute 49Neoplasm Metastasis 46Multiple Myeloma 40Breast Neoplasms 33Prostatic Neoplasms 30Colorectal Neoplasms 27Lymphoma 26Lung Neoplasms 26Leukemia, Lymphocytic, Chronic, B-Cell 24Pancreatic Neoplasms 23Myelodysplastic Syndromes 22Lymphoma, Large B-Cell, Diffuse 21Triple Negative Breast Neoplasms 19Ovarian Neoplasms 17Melanoma 17Carcinoma, Non-Small-Cell Lung 17Burkitt Lymphoma 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Neoplasms 15Carcinoma, Renal Cell 15Leukemia, Myelomonocytic, Chronic 13Glioma 13Neuroblastoma 12Lymphoma, Mantle-Cell 12Lymphoma, Follicular 12Sarcoma 11Lymphoma, Non-Hodgkin 11Fallopian Tube Neoplasms 11Endometrial Neoplasms 11Myeloproliferative Disorders 10

Interventions

Imatinib Mesylate 12Sunitinib 10ripretinib 5regorafenib 4Blood Specimen Collection 3envafolimab 2Specimen Handling 2Paclitaxel 2Magnetic Resonance Spectroscopy 2IDRX-42 2Biopsy 2trastuzumab deruxtecan 1spartalizumab 1ribociclib 1pemigatinib 1palbociclib 1olverembatinib 1nilotinib 1guadecitabine 1binimetinib 1avelumab 1avapritinib 1atezolizumab 1apatinib 1Temozolomide 1TAS-116 1Surgical Instruments 1Sorafenib 1Rogaratinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gastrointestinal Stromal Tumors × Biopsy × 1 year × Clear all
NCT04595747 2026-05-22

Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
48 enrolled
GastrointestinalSarcoma

Sarcoma, Gastrointestinal Stromal Tumors

NCT01991379 2025-12-04

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
75 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡